摘要
目的分析酪酸梭菌活菌胶囊联合英夫利西单抗治疗溃疡性结肠炎的效果及对肠道菌群、血清白细胞介素-17(IL-17)、可溶性细胞间黏附分子-1(sICAM-1)、肿瘤坏死因子-α(TNF-α)水平的影响。方法选择2019年10月至2021年10月莆田市秀屿区医院收治的溃疡性结肠炎患者122例,参照随机数表法分为联合组(n=61)和单抗组(n=61)。联合组予以酪酸梭菌活菌胶囊联合英夫利西单抗治疗,单抗组予以英夫利西单抗治疗,均治疗3个月。比较两组疗效、不良反应、治疗前后肠道菌群数量、血清IL-17、sICAM-1、TNF-α水平。结果联合组治疗后总有效率为91.80%高于单抗组的77.05%,差异有统计学意义(P<0.05);联合组治疗后血清IL-17、sICAM-1、TNF-α水平均低于单抗组,差异有统计学意义(P<0.05);联合组治疗后大肠埃希菌、肠球菌数量均少于单抗组,联合组双歧杆菌、乳杆菌数量均高于单抗组,差异有统计学意义(P<0.05);联合组与单抗组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论应用酪酸梭菌活菌胶囊联合英夫利西单抗治疗溃疡性结肠炎可调节肠道菌群数量,降低血清IL-17、sICAM-1、TNF-α水平,进而提高疗效,且安全性好。
Objective To analyze the efficacy of Clostridium butyricum capsule combined with infliximab on ulcerative colitis and its impacts on intestinal flora,serum interleukin-17(IL-17),soluble intercellular adhesion molecule-1(sICAM-1)and tumor necrosis factor-α(TNF-α)levels.Methods A total of 122 patients with ulcerative colitis admitted to and treated in Putian Xiuyu District Hospital from October 2019 to October 2021 were selected,and they were divided into the combination group(n=61)and the monoclonal antibody group(n=61)according to the random number table method.The combination group was treated with Clostridium butyricum capsules combined with infliximab,while the monoclonal antibody group was treated with infliximab.All patients were treated for 3 months.The therapeutic efficacy,adverse reactions(ARs),intestinal flora before and after treatment,serum IL-17,sICAM-1 and TNF-αlevels were compared between the two groups.Results The total effective rate of the combined group was 91.80%higher than 77.05%of the monoclonal antibody group,with statistically significant difference(P<0.05);The levels of serum IL-17,sICAM-1,TNF-αafter treatment in combination group were lower than those in the monoclonal antibody group,with statistically significant differences(P<0.05);After treatment,the number of Escherichia coli and enterococcus in the combined group was less than that in the monoclonal antibody group,and the number of bifidobacteria and lactobacillus in the combined group was higher than that in the monoclonal antibody group,with statistically significant differences(P<0.05);There was no significant difference in the total incidence of adverse reactions between the combination group and the monoclonal antibody group(P>0.05).Conclusion The application of Clostridium butyricum capsule combined with infliximab in the treatment of ulcerative colitis can regulate the number of intestinal flora,reduce the levels of serum IL-17,sICAM-1 and TNF-α,and then improve the therapeutic efficacy,which has good safety.
作者
林金祥
LIN Jinxiang(DepartmentⅡof Internal Medicine,Xiuyu Hospital of Putian City,Fujian,Putian 351146,China)
出处
《中国医药科学》
2022年第21期197-200,共4页
China Medicine And Pharmacy
